Conclusion
The BAT can be seen as a surrogate of immediate allergic reactions in vitro and thus support the diagnosis of allergic diseases and its monitoring during immunomodulatory treatments (Table 4). A robust laboratory method which can provide consistent and reliable results that have been clinically validated can be extremely valuable both for clinical practice and for clinical trials into existing and novel treatments for allergic disease. Standardisation and continuous quality assurance as well as training of health care professionals on the interpretation of BAT results are important for further implementation of BAT in clinical practice and allergy research.